These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 15083599

  • 1. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR, Tian J, Goltzman D.
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J.
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR, Tian J, Nakane M, Ma J, Fey TA, Kroeger P, Fryer RM, Reinhart GA.
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [Abstract] [Full Text] [Related]

  • 5. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 6. Are vitamin D receptor activators useful for the treatment of thrombosis?
    Wu-Wong JR.
    Curr Opin Investig Drugs; 2009 Sep; 10(9):919-27. PubMed ID: 19705334
    [Abstract] [Full Text] [Related]

  • 7. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
    Brown AJ, Slatopolsky E.
    Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
    [Abstract] [Full Text] [Related]

  • 9. 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action.
    Nezbedova P, Brtko J.
    Endocr Regul; 2004 Mar; 38(1):29-38. PubMed ID: 15147236
    [Abstract] [Full Text] [Related]

  • 10. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
    Wolf M, Thadhani R.
    Semin Dial; 2005 Mar; 18(4):302-6. PubMed ID: 16076353
    [Abstract] [Full Text] [Related]

  • 11. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR, Melnick J.
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [Abstract] [Full Text] [Related]

  • 12. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M.
    J Nephrol; 2007 Mar; 20(1):3-9. PubMed ID: 17347966
    [Abstract] [Full Text] [Related]

  • 13. Vitamin D treatment in chronic kidney disease.
    Andress DL.
    Semin Dial; 2005 Mar; 18(4):315-21. PubMed ID: 16076355
    [Abstract] [Full Text] [Related]

  • 14. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 15. [Recent progress of study on vitamin D analogs].
    Kittaka A, Saito N, Takano M.
    Clin Calcium; 2006 Jul; 16(7):1154-65. PubMed ID: 16816476
    [Abstract] [Full Text] [Related]

  • 16. Vitamin D analogs: novel therapeutic agents for cardiovascular disease?
    Reinhart GA.
    Curr Opin Investig Drugs; 2004 Sep; 5(9):947-51. PubMed ID: 15503649
    [Abstract] [Full Text] [Related]

  • 17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
    Jones G, Hogan DB, Yendt E, Hanley DA.
    CMAJ; 1996 Oct 01; 155(7):955-61. PubMed ID: 8837546
    [Abstract] [Full Text] [Related]

  • 18. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr 01; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D receptor ligands for osteoporosis.
    Cheskis BJ, Freedman LP, Nagpal S.
    Curr Opin Investig Drugs; 2006 Oct 01; 7(10):906-11. PubMed ID: 17086935
    [Abstract] [Full Text] [Related]

  • 20. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
    Dusilová Sulková S.
    Vnitr Lek; 2012 Nov 01; 58(11):839-49. PubMed ID: 23256830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.